Medicina clinica
-
Etiological diagnosis of community-acquired pneumonia (CAP) is only reached in 30-40% of cases, which frequently requires keeping empirical antibiotic regimens. The new nucleic acid amplification techniques (NAAT) in respiratory samples raise the possibility of improving this clinical practice. Our objective was to analyze TAANs contribution estimating both their costs and benefits. ⋯ 64 cases were documented. An etiological diagnosis was made in 65.6%: 10.9% were obtained by conventional techniques and the rest (54.7%) by TAAN. These tests' results led to antimicrobial regimen's modification in 88.9% of cases and isolations in 78.5% CONCLUSIONS: Compared to TAAN's economic cost, it is worth considering its contributions, such as antimicrobials' reduction, ecological pressure, and isolations' indications.
-
Cardiac implantable electronic devices have transformed medicine as they improve quality of life and prevent premature death. In palliative care settings, deactivation of these devices must be discussed, particularly at end-of-life. In terminally ill patients it is consensual to recommend implantable cardioverter defibrillator deactivation once shocks are frequent and painful. ⋯ Regarding cardiac resynchronization therapy, deactivation is not recommended as it can worsen symptoms. Left ventricular assistance device deactivation at end-of-life is a well-accepted practice, since it has the benefit of ending the physical burden associated with the device. Advance care planning should be encouraged and patients should be informed that deactivation is possible.
-
Multicenter Study
Prevalence of Fabry disease in patients with left ventricular hypertrophy and renal involvement (PrEFaCe).
Fabry disease (FD) causes glycosphingolipid accumulation in the vascular endothelium, with predominantly cardiac and renal involvement. Its prevalence in patients with concomitant involvement of these two organs is unknown. The objective of the study was to determine the prevalence of FD in patients with left ventricular hypertrophy and any degree of chronic kidney disease. ⋯ FD is an important cause of left ventricular hypertrophy and chronic kidney disease. Genetic diagnosis is crucial for avoiding biases and ensuring accurate identification of FD, especially in women. The results support the inclusion of this disease in the differential diagnosis of patients with ventricular hypertrophy ≥13mm and chronic kidney disease.